CLINICAL_TRIALS
trial_result
· 2019-08-28
Clinical Trial Update: Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients [Phase 3]
Summary
Phase 3 trial evaluating adjuvant axitinib in high-risk renal cell carcinoma; study terminated with posted results in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SFJ Pharma Ltd. II | Conditions: Clear Cell Renal Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2019-08-28